These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30983432)

  • 1. Are biological drugs effective and safe in older severe asthmatics?
    Benfante A; Principe S; Battaglia S; Scichilone N
    Expert Opin Drug Saf; 2019 May; 18(5):369-380. PubMed ID: 30983432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment.
    Bagnasco D; Heffler E; Testino E; Passalacqua G; Canonica GW
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):113-120. PubMed ID: 30632416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of omalizumab in asthma.
    Tan RA; Corren J
    Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A drug safety review of treating eosinophilic asthma with monoclonal antibodies.
    Mitchell P; Leigh R
    Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New guidelines and new therapy options in severe asthma].
    Einecke D
    MMW Fortschr Med; 2016 May; 158(9):18-9. PubMed ID: 27155682
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal Antibodies for the Management of Severe Asthma.
    Rubinsztajn R; Chazan R
    Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma biologics: Comparing trial designs, patient cohorts and study results.
    Doroudchi A; Pathria M; Modena BD
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):44-56. PubMed ID: 31655122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
    Dávila I; Quirce S; Olaguibel JM
    J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologics for Asthma and Risk of Infection: Cause for Concern?
    Lopes JP; Desai M
    Immunol Allergy Clin North Am; 2019 Aug; 39(3):429-445. PubMed ID: 31284931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Treatments for Asthma.
    Huang J; Pansare M
    Pediatr Clin North Am; 2019 Oct; 66(5):925-939. PubMed ID: 31466682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting interleukins to treat severe asthma.
    Gibeon D; Menzies-Gow AN
    Expert Rev Respir Med; 2012 Aug; 6(4):423-39. PubMed ID: 22971067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.